Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Merck & Co., Inc. (MRK) vs Vanguard Growth Index Fund ETF (VUG) Price & Performance

Merck & Co., Inc.Trade
Vanguard Growth Index Fund ETFTrade

Price performance (Past 24H)

Key statistics

Merck & Co., Inc. vs Vanguard Growth Index Fund ETF — how do they compare? Merck & Co., Inc. trades at $133.65 (market cap $321.77B), while Vanguard Growth Index Fund ETF trades at $88.97. The key difference: Merck & Co., Inc. pays a 2.61% dividend while Vanguard Growth Index Fund ETF pays none. Which is the better fit depends on your goals.

MRKVUG
Market Cap
$321.77B
Sector
HealthSector/Thematic
52-Week High
$131.84$90.29
52-Week Low
$77.60$70.00
Enterprise Value
$368.53B
Dividend Yield
2.61%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Merck & Co., Inc.

Merck & Co. (MRK) trades at $133.64, up 2.09% today, with a bullish technical signal from moving averages and strong institutional buying interest. The company reported solid earnings beats in recent quarters, with Q3 2026 EPS expected at $2.27. Revenue for 2025 reached $65.01B, and net income was $18.25B, though the P/E ratio of 104.34 suggests high valuation expectations. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.

Outlook: MRK's growth is supported by strategic acquisitions and a dominant oncology franchise, but risks include high valuation multiples and competitive pressures. The consensus price target of $140.36 implies modest upside, with 68% of analysts rating it a Buy. Investors should monitor execution on the Terns integration and Q3 earnings results for catalysts.

Vanguard Growth Index Fund ETF

VUG trades at $88.94, down 0.27% on the day, with a bullish technical signal driven by moving averages. The ETF shows strong institutional accumulation, with multiple firms increasing holdings by over 500% in Q2 2026. RSI levels above 70 indicate potential overbought conditions, while support sits near $88 and resistance at $90.

The outlook remains positive given institutional confidence and growth ETF appeal, but high RSI suggests near-term consolidation risk. Investors face volatility from market sentiment shifts, though long-term growth exposure aligns with historical outperformance versus the S&P 500.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.

Read more on MRK

About Vanguard Growth Index Fund ETF

VUG is an index-based ETF that tracks the CRSP US Large Cap Growth Index, providing concentrated exposure to the largest and fastest-growing companies in the United States. It focuses on stocks with high growth potential across tech, communication, and consumer sectors, serving as a low-cost, high-conviction core holding for long-term capital appreciation.

Read more on VUG